Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

  • End date
    Dec 22, 2024
  • participants needed
  • sponsor
    Sorrento Therapeutics, Inc.
Updated on 7 October 2022
measurable disease
bone marrow procedure
refractory multiple myeloma


This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.


This is a phase 1b, open-label, multicenter, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

The study will determine the MTD and RP2D, assessing safety and preliminary efficacy using a conventional 3+3 study design with two design stages, an ascending dose stage followed by an expansion study.

Patients will be enrolled sequentially within each cohort and between cohorts during the dose escalation portion of the study with the staggered intervals of at least 28 days. Only one patient will be allowed to receive study treatment at any time through the end of the staggering period before the next subject may begin study treatment.

Condition Multiple Myeloma
Treatment STI-1492
Clinical Study IdentifierNCT05007418
SponsorSorrento Therapeutics, Inc.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments
Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma
Pulse oximetry ≥ 92% on room air
Have a life expectancy ≥ 12 weeks
Be willing and able to comply with the study schedule and all study requirements
Willing to follow contraception guidelines

Exclusion Criteria

Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose
Treatment with any cellular therapy within 8 weeks prior to start of study dose
Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies
A history of brain metastasis or spinal cord compression
Has an ECOG performance status (PS) ≥ 3
Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant
Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM
Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin
Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
Is currently pregnant or breast feeding or planning on either during the study
Has an active bacterial, viral, or fungal infection
Has active plasma cell leukemia
Has extramedullary plasmacytoma(s)
Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
Has left ventricular ejection fraction (LVEF) < 40%
Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission
Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note